Previous close | 15.90 |
Open | 15.87 |
Bid | 15.92 x 200 |
Ask | 16.01 x 200 |
Day's range | 15.85 - 15.99 |
52-week range | 12.22 - 16.86 |
Volume | |
Avg. volume | 640,615 |
Market cap | 997.243M |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | 7.13 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 08 Sept 2015 |
1y target est | N/A |
BURLINGAME, Calif., June 03, 2024--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL
BURLINGAME, Calif., May 08, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2024, and highlighted select corporate achievements.
BURLINGAME, Calif., May 08, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the BofA Securities Health Care Conference in Las Vegas, NV on Wednesday, May 15, 2024 at 9:20 a